Journal: Drug Invention Today

Article Id: JPRS-Pcol-00004475
Title: Metabolic and neuropsychic status in chronic brain ischemia: Correction of disorders
Category: Pharmacology
Section: Research Article
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology
  • Abstract

    Introduction: Chronic brain ischemia (CBI) is one the causes of disability and Russian population mortality, moreover inflicting a great economic loss to the society. The development of a strategy for pharmacological correction of this pathology is one of the urgent, timely tasks. The aim of the study is to determine the clinical and laboratory efficacy of glutoxim among patients with CBI of I and II stages. Materials and Methods: A total of 48 patients at the age of 50 ± 5 years from the Neurological Department of the BME “Kursk Regional Clinical Hospital” were under constant observation with a verified diagnosis of CBI in presence with II stage hypertensive disease, thus 24 patients with CBI of the I stage and the II stage, respectively, received basic pharmacological therapy (enalapril, vinpocetine, ceraxon, and mexicor). Half of the patients with each stage of the disease received an additional preparation with immunomodulatory effect glutoxim. Metabolic and immunological disorders were assessed by total antioxidant activity, acylhydroperoxides, malondialdehyde, stable metabolites of nitric oxide concentrations in plasma and erythrocytes, catalase activity, superoxide dismutase, plasma levels of C-reactive protein, endothelin-1, erythropoietin, neopterin, and immunologically – according to the concentrations of cytokines tumor necrosis factor-alpha, interleukin 1β, interleukin 17, and interferon-gamma in blood plasma. The complex of patients’ examination included, in addition to general clinical status, the assessment of neuropsychic one. Results and Discussion: In the case of CBI, to a greater extent on II stage, in the presence of the hypertensive disease, similar metabolic disorders were revealed, indicating the activation of lipid peroxidation, the development of oxidative stress and endothelial dysfunction. The inclusion of glutoxim in complex pharmacotherapy contributes, especially at an early stage of CBI, to a reduction in the severity of subjective disorders, indicators of neurological status, cognitive dysfunction, and laboratory metabolic parameters. Conclusion: The obtained data indicate the effectiveness of glutoxim in the basic pharmacological treatment of CBI.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    A. I. Konoplya*, N. A. Bystrova, A. A. Shulginova, O. A. Sunyaikina, S. A. Dolgareva, O. V. Khorlyakova

    Affiliation(s) Name:

    Department of Biochemistry, Federal State Budget Educational Institution of Higher Education “Kursk State Medical University” of the Ministry of Health of the Russian Federation, 305041, Kursk, Russia (rector – Professor Lazarenko V.A.).

    *Corresponding author: A. I. Konoplya, Department of Biochemistry, Kursk State Medical University, Kursk, Russia.

  • View Article File in pdf format.

    Article File
  • View Article Citation Here.

    0 View More
  • How to Cite my Article.

    Author:

    A. I. Konoplya*, N. A. Bystrova, A. A. Shulginova, O. A. Sunyaikina, S. A. Dolgareva, O. V. Khorlyakova

    Title:Metabolic and neuropsychic status in chronic brain ischemia: Correction of disorders
    Journal:Drug Invention Today
    Vol(issue):12 (November )
    Year:2019
    Page No: (2741-2747)
  • Experimental Methods Keywords

    Methodology:Chronic brain ischemia, Cognitive, Glutoxim, Metabolic disorders, Neurologic
    Research Materials:enalapril, vinpocetine, ceraxon, and mexicor

Keywords

Chronic brain ischemia Cognitive Glutoxim Metabolic disorders Neurologic

Our Services

Most Downloaded List